A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
FISH, MDS/MYELOID PANEL
Test CodeFISHMDS
Quest Code
19799
CPT Codes
88275 (x3), 88271 (x6)
Includes
Methodology: Four probe sets associated with myelodysplastic syndrome (MDS) are included in this panel: -5/5q-, -7/7q-, +8, 20q-. 100-300 interphase nuclei are scored for each probe set to detect gain, loss, or rearrangements of the probe regions.
Preferred Specimen
5 mL whole blood or 3 mL bone marrow collected in sodium heparin (green-top) tube
Minimum Volume
1 mL whole blood or bone marrow
Other Acceptable Specimens
Whole blood or bone marrow collected in: Sodium heparin (royal blue-top) or sodium heparin lead-free (tan-top) tube
Instructions
Clinical history/reason for referral is required with test order. Prior therapy and transplant history should be provided.
Submit 3-5 mL whole blood or 1-3 mL bone marrow collected in a sodium heparin tube.
Specimen viability decreases during transit. Send specimen to testing laboratory for viability determination. Do not freeze. Do not reject.
Submit 3-5 mL whole blood or 1-3 mL bone marrow collected in a sodium heparin tube.
Specimen viability decreases during transit. Send specimen to testing laboratory for viability determination. Do not freeze. Do not reject.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: See instructions
Refrigerated: See instructins
Frozen: See instructions
Refrigerated: See instructins
Frozen: See instructions
Methodology
Fluorescence in situ Hybridization (FISH)
FDA Status
This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics. It has not been cleared or approved by the U.S. Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.
Setup Schedule
Set up: Sun-Fri; Report available: 7 days
Reference Range
See Laboratory Report
Clinical Significance
Prognostic investigation in patients with myelodysplasia or other myeloid malignancies. Among the patients with myelodysplastic syndromes (MDS), 45-50% have a least one chromosome rearrangement, the most common of which can be detected using this fluorescence in situ hydridization (FISH) panel (-5/5q-,-7/7q-,+8,20q-). This panel of FISH probes can increase the detection rate of chromosome abnormalities at diagnosis and aid in follow-up testing for clinically significant chromosome abnormalities in MDS. The identification of the specific chromosome regions involved in a patient's disease may play a significant role in treatment decisions as MDS targeted therapies are developed.
Performing Laboratory
Quest Diagnostics Nichols Institute
14225 Newbrook Drive
Chantilly, VA 20153
Last Updated: April 21, 2021